Loading...
Market
First significant treatment advancement using PRISM by 2025?
2
Resolution / Starting Odds
Alzheimer's Disease • 25%
Parkinson's Disease • 25%
Schizophrenia • 25%
Other • 25%
Published studies or clinical trial results
Story
E11 Bio's Andrew C. Payne Achieves 100x Cost Reduction in Brain Mapping for Curing Disorders with PRISM Technology
Dec 3, 2024, 03:27 PM
E11 Bio has announced a significant advancement in brain mapping technology, achieving a reduction in costs by 100 times. This breakthrough, referred to as PRISM, enables the creation of full brain maps more quickly and efficiently than previously possible. The development is expected to enhance research in connectomics at both human and mouse scales, which is critical for addressing brain disorders, advancing artificial intelligence systems, and simulating human brain functions. The team, led by Andrew C. Payne, has been working diligently on this project, which promises to revolutionize the field of neuroscience and AI.
View original story
Similar markets
Cancer • 25%
Infectious Diseases • 25%
Autoimmune Diseases • 25%
Other • 25%
Cancer Research • 25%
Genetic Disorders • 25%
Neuroscience • 25%
Other • 25%
Cancer treatment • 25%
Neurodegenerative diseases • 25%
Infectious diseases • 25%
Cardiovascular diseases • 25%
New drug approval • 25%
Major clinical trial success • 25%
New treatment guidelines • 25%
Other • 25%
Phase 2 Trial Completion • 25%
FDA Approval • 25%
Commercial Launch • 25%
None of the Above • 25%
Parkinson's Disease • 25%
Heart Disease • 25%
Spinal Cord Injury • 25%
Other • 25%
Phase 1 completion • 25%
Phase 2 completion • 25%
Phase 3 completion • 25%
No significant milestone • 25%
Anti-aging • 25%
Detoxification • 25%
General wellness • 25%
Other • 25%
SMA Type 3 • 25%
SMA Type 2 • 25%
Both SMA Type 2 and 3 • 25%
Other • 25%
Yes • 50%
No • 50%
